Tetramethylpyrazine and paeoniflorin combination(TMP-PF)alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway

扫码查看

原文链接

万方数据
维普

外文摘要：Atherosclerosis remains a great threat to human health worldwide.Previous studies found that tetramethylpyrazine(TMP)and paeoniflorin(PF)combination(TMP-PF)exerts anti-atherosclerotic effects in vitro.However,whether TMP-PF improves atherosclerosis in vivo needs further exploration.The present study aims to assess the anti-atherosclerotic properties of TMP-PF in ApoE-/-mice and explore the related molecule mechanisms.Results showed that TMP and high-dose TMP-PF decreased serum triglyceride and low-density lipoprotein cholesterol levels,suppressed vascular endothelial growth factor receptor 2(VEGFR2)and nuclear receptor subfamily 4 group A member 1(NR4A1)expression in aortic tissues,inhibited plaque angiogenesis,reduced plaque areas,and alleviated atherosclerosis in ApoE-/-mice.Also,TMP-PF exhibited a better modulation effect than TMP or PF alone.However,NR4A1 agonist abolished the anti-atherosclerotic effects of TMP-PF.In conclusion,TMP-PF was first found to alleviate atherosclerosis progression by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway,indicating that TMP-PF had a positive effect on reducing hyperlipemia and attenuating atherosclerosis development.

外文关键词：

AtherosclerosisHyperlipemiaAngiogenesisPlaque stabilityChinese medicineTetramethylpyrazinePaeoniflorin

作者：

Rong Yuan、Qiqi Xin、Weili Shi、Yu Miao、Zhengchuan Zhu、Yahui Yuan、Ying Chen、Xiaoning Chen、Sean Xiao Leng、Keji Chen、Weihong Cong

展开 >

作者单位：

Cardiovascular Diseases Laboratory,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China

National Clinical Research Center for Chinese Medicine Cardiology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China

School of Health Economics and Management,Nanjing University of Chinese Medicine,Nanjing 210023,China

Department of Otolaryngology,Jiangsu Province Hospital of Chinese Medicine,Nanjing 210029,China

Division of Geriatric Medicine and Gerontology,Department of Medicine,Johns Hopkins University School of Medicine,Baltimore 21224,United States

展开 >

基金：

Fundamental Research Funds for the Central Public Welfare Research InstitutesFundamental Research Funds for the Central Public Welfare Research InstitutesNational Natural Science Foundation of ChinaCACMS Innovation FundIrma and Paul Milstein Program for Senior Health of Milstein Medical Asian American Partnership Foundation

项目编号：

ZZ11-061ZZ14-YQ-00782004193CI 2021A00914

出版年：

2024

DOI：

10.26599/FSHW.2022.9250212

食品科学与人类健康(英文)

CSTPCD

ISSN：

年,卷(期)：2024.13(5)